This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snyder, E. L. Articles by Dowdy, S. F. Search for Related Content PubMed PubMed Citation Articles by Snyder, E. L. Articles by Dowdy, S. F.

Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides

¹ Howard Hughes Medical Institute and Departments of ² Cellular and Molecular Medicine and ³ Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla, California

Requests for reprints: Steven F. Dowdy, Howard Hughes Medical Institute and Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, 9600 Gilman Drive, La Jolla, CA 92037-0686. Phone: 858-534-7772; E-mail: sdowdy{at}ucsd.edu.

Protein transduction domains (PTDs), such as the TAT PTD, have been shown to deliver a wide variety of cargo in cell culture and to treat preclinical models of cancer and cerebral ischemia. The TAT PTD enters cells by a lipid raft–dependent macropinocytosis mechanism that all cells perform. Consequently, PTDs resemble small-molecule therapeutics in their lack of pharmacologic tissue specificity in vivo. However, several human malignancies overexpress specific receptors, including HER2 in breast cancer, GnRH in ovarian carcinomas, and CXC chemokine receptor 4 (CXCR4) in multiple malignancies. To target tumor cells that overexpress the CXCR4 receptor, we linked the CXCR4 DV3 ligand to two transducible anticancer peptides: a p53-activating peptide (DV3-TATp53C') and a cyclin-dependent kinase 2 antagonist peptide (DV3-TAT-RxL). Treatment of tumor cells expressing the CXCR4 receptor with either the DV3-TATp53C' or DV3-TAT-RxL targeted peptides resulted in an enhancement of tumor cell killing compared with treatment with nontargeted parental peptides. In contrast, there was no difference between DV3 targeted peptide and nontargeted, parental peptide treatment of non-CXCR4-expressing tumor cells. These observations show that a multidomain approach can be used to further refine and enhance the tumor selectivity of biologically active, transducible macromolecules for treating cancer.

This article has been cited by other articles:

				W.-F. Ma, J. Du, L.-P. Fu, R. Fang, H.-Y. Chen, and S.-H. Cai Phenotypic Knockout of CXCR4 by a Novel Recombinant Protein TAT/54R/KDEL Inhibits Tumors Metastasis Mol. Cancer Res., October 1, 2009; 7(10): 1613 - 1621. [Abstract] [Full Text] [PDF]

				L. Zhang, E. Levi, P. Majumder, Y. Yu, A. Aboukameel, J. Du, H. Xu, R. Mohammad, J. S. Hatfield, A. Wali, et al. Transactivator of transcription-tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo Mol. Cancer Ther., May 1, 2007; 6(5): 1661 - 1672. [Abstract] [Full Text] [PDF]

				C. Kunz, C. Borghouts, C. Buerger, and B. Groner Peptide Aptamers with Binding Specificity for the Intracellular Domain of the ErbB2 Receptor Interfere with AKT Signaling and Sensitize Breast Cancer Cells to Taxol Mol. Cancer Res., December 1, 2006; 4(12): 983 - 998. [Abstract] [Full Text] [PDF]